Christopher T. RitchlinDirector, Professor | Rochester, New York
Dr. Ritchlin is also the Director of the Clinical Immunology Research Unit where he is the principle investigator on several clinical trials testing the efficacy of anti-TNF agents and other biologic molecules in the treatment of psoriatic and rheumatoid arthritis and ankylosing spondylitis. In the Clinical Immunology Research Unit, patient oriented research is conducted on multiple levels. Investigator New Drug (IND) trials of novel agents (adalimumab, rituximab) in the treatment of PsA and AS have been completed or are about to start. Additional trials have been performed to study the effect of TNF inhibition on the frequency of osteoclast precursors and enhancing bone marrow edema in PsA.